FIM
MBRX icon

FWL Investment Management’s Moleculin Biotech MBRX Stock Holding History

FWL Investment Management’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-11
Closed -$1.64K – 257
2024
Q1 		$1.64K Buy
+11
New +$2.35K ﹤0.01% 212

Other funds holding MBRX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AWM
Atticus Wealth Management Palm Beach Gardens, Florida $420M AUM 23.31% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
NFSG
Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SSB
Sandy Spring Bank Olney, Maryland $2.38B AUM 8.14% 1-Year Est. Return

FWL Investment Management's MBRX Position: Q2 2024 in Review

FWL Investment Management sold out of Moleculin Biotech (MBRX) in Q2 2024, closing a stake of 11 shares — an estimated $1.64K sold.

FWL Investment Management first reported a position in MBRX in Q1 2024 and held it in 1 quarter. The position peaked at $1.64K in Q1 2024. 14 funds tracked by Wall St. Rank hold MBRX as of Q2 2024.

  • FWL Investment Management reported no remaining Moleculin Biotech position as of Q2 2024 after selling out during the quarter.
  • FWL Investment Management sold 11 Moleculin Biotech shares in Q2 2024, an estimated $1.64K.
  • FWL Investment Management first reported a position in Moleculin Biotech in Q1 2024 and held it in 1 quarter.
  • FWL Investment Management's Moleculin Biotech position peaked at $1.64K in Q1 2024.
  • 14 funds tracked by Wall St. Rank held Moleculin Biotech as of Q2 2024.

Based on FWL Investment Management's 13F filing for Q2 2024, filed 13 Aug 2024.